Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AVITA Medical Inc
RCEL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$13.80
0.66
5.02%
Últ. Act.: Oct 21, 4:00 AM
$13.99
0.85
6.47%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
AVITA Medical Financials
AVITA Medical (RCEL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
Avi Kapoor
PRO
AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est
AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate.
Benzinga Newsdesk
PRO
AVITA Medical Q2 EPS $(0.25) Beats $(0.29) Estimate, Sales $21.702M Beat $20.167M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 34.21 percent increase over losses of $(0.38) per share from
Benzinga Newsdesk
PRO
AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $82.258M Est
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $82.258 million estimate.
Benzinga Newsdesk
PRO
AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 33.96 percent increase over losses of $(0.53) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
